EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

IL-1β and HMGB1 in Epileptogenesis: Recent Advances and Clinical Translation

Huali Geng, Leihao Sha, Lei Chen iD

Pharmaceuticals · 10.10.2025 · 18 (10) · 1522

DOI: 10.3390/ph18101522 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 10.10.2025. Verfasst von Huali Geng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, China. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sichuan Science and Technology Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epilepsy is one of the most prevalent and disabling neurological disorders, affecting approximately one percent of the population. Due to the complex pathophysiology underlying drug-resistant epilepsy, nearly one-third of patients with epilepsy do not benefit from current treatments. Neuroinflammation is one of the most well-studied pathways in epileptogenesis, and inflammatory mediators play a crucial role in this process. The IL-1β/IL-1R1/IL-1Ra and HMGB1/TLR4 pathways play significant roles in epileptogenesis in both animal and human studies. Interventional investigations on the IL-1β/IL-1R1/IL-1Ra and HMGB1/TLR4 pathways showed antiseizure effects, suggesting that these pathways could be therapeutic targets for epilepsy. However, related targeted treatments are limited in clinical practice. In this work, we evaluated the advances of the IL-1β/IL-1R1/IL-1Ra and HMGB1/TLR4 pathways in epileptogenesis, as well as clinical trials or interventional investigations of current medications or substances targeting these pathways. To facilitate clinical translation, we highlighted the gap between research advancements and clinical practice and presented several strategies for closing the gap to fulfill the urgent requirements of patients with epilepsy.

Schlagwörter

Stichwörter der Autor:innen

HMGB1IL-1RIL-1βTLR4clinical translationepilepsytherapeutic targets

Autor:innen und Institutionen

  • Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, China.
  • High Altitude Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China.

ORCID-Profile: Lei Chen

Förderung

  • Sichuan Science and Technology Program

Zitieren

APA

Geng, H., Sha, L., & Chen, L. (2025). IL-1β and HMGB1 in Epileptogenesis: Recent Advances and Clinical Translation. Pharmaceuticals, 18(10), 1522. https://doi.org/10.3390/ph18101522

Vancouver

Geng H, Sha L, Chen L. IL-1β and HMGB1 in Epileptogenesis: Recent Advances and Clinical Translation. Pharmaceuticals. 2025;18(10):1522. doi:10.3390/ph18101522

BibTeX
@article{Geng2025,
  author = {Geng, Huali and Sha, Leihao and Chen, Lei},
  title = {IL-1β and HMGB1 in Epileptogenesis: Recent Advances and Clinical Translation},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {10},
  pages = {1522},
  doi = {10.3390/ph18101522}
}
Kostenlos starten →